Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Shockwave Medical, Inc. (SWAV) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture between Shockwave Medical, Inc. and U.S. Bank Trust Company, National Association, as trustee (including the form of 1.00% Convertible Senior Notes due 2028)",
"Form of Capped Call Transaction Confirmation"
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"SHOCKWAVE MEDICAL PRICES UPSIZED PRIVATE OFFERING OF $650.0 MILLION OF 1.00% CONVERTIBLE SENIOR NOTES DUE 2028"
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"SHOCKWAVE MEDICAL ANNOUNCES PROPOSED PRIVATE OFFERING OF $500.0 MILLION OF CONVERTIBLE SENIOR NOTES"
08/07/2023 8-K Quarterly results
Docs: "Shockwave Medical Reports Second Quarter 2023 Financial Results SANTA CLARA, Calif., Aug. 07, 2023 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023. Recent Highlights Recognized revenue of $180.2 million for the second quarter of 2023, representing an increase of 49% from the same period in 2022 As part of the Fiscal Year 2024 Medicare Hospital Inpatient Prospective Payment System final rule, the Centers for Medicare & Medicaid Services created three new coronary IVL-specific MS-DRGs, which will become effective October 1, 2023. These new codes are associated with higher payments than the MS-DRG payments for o..."
06/01/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND AMENDMENT TO OFFICE LEASE"
05/17/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SHOCKWAVE APPOINTS KEVIN BALLINGER TO BOARD OF DIRECTORS"
05/08/2023 8-K Quarterly results
Docs: "Shockwave Medical Reports First Quarter 2023 Financial Results SANTA CLARA, Calif., May 08, 2023 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023. Recent Highlights Recognized revenue of $161.1 million for the first quarter of 2023, representing an increase of 72% from the same period in 2022 Announced the full U.S. commercial availability of the Shockwave L 6 Peripheral IVL Catheter following clearance by the U.S. Food and Drug Administration Centers for Medicare & Medicaid Services , as part of the calendar year 2024 Medicare Hospital Inpatient Prospective Payment System proposed rule, proposed three newl..."
01/17/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition  Interactive Data
Docs: "SHOCKWAVE MEDICAL, INC. as Purchaser",
"FORM OF SUPPORT AND VOTING AGREEMENT",
"FORM OF CONVERSION, SUPPORT AND VOTING AGREEMENT",
"SHOCKWAVE MEDICAL ANNOUNCES AGREEMENT TO ACQUIRE NEOVASC"
12/23/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Second Amended and Restated Bylaws of Shockwave Medical, Inc. (as amended and restated on December 22, 2022)",
"Second Amended and Restated Bylaws of Shockwave Medical, Inc. (as amended and restated on December 22, 2022)"
11/07/2022 8-K Quarterly results
Docs: "Shockwave Medical Reports Third Quarter 2022 Financial Results SANTA CLARA, Calif., Nov. 07, 2022 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022. Recent Highlights Recognized revenue of $131.3 million for the third quarter of 2022, representing an increase of 102% from the same period in 2021 Received FDA Clearance for the Shockwave IVL System with the Shockwave L 6 Peripheral IVL Catheter Received CE marking for the Shockwave C 2+ coronary catheter in Europe Granted reimbursement for the Shockwave C 2 Coronary IVL Catheter by the Japanese Ministry of Health, Labour and Welfare in Japan “Our third qua..."
10/20/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/30/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/22/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/17/2022 8-K Quarterly results
Docs: "Shockwave Medical Reports Fourth Quarter and Full Year 2021 Financial Results SANTA CLARA, Calif., Feb. 17, 2022 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2021. Recent Highlights Recognized revenue of $84.2 million for the fourth quarter of 2021 and $237.1 million for the full year of 2021, representing increases of 271% and 250%, respectively, from the same periods in 2020 Centers for Medicare & Medicaid Services reassigned the payment for peripheral IVL procedures performed on above the knee arteries in the hospital outpatient setting, thereby meaningfully increasing the payments hospit..."
11/08/2021 8-K Quarterly results
Docs: "Shockwave Medical Reports Third Quarter 2021 Financial Results SANTA CLARA, Calif., Nov. 08, 2021 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2021. Recent Highlights Recognized revenue of $65.2 million for the third quarter of 2021, representing an increase of 233% from the same period in 2020 DISRUPT PAD III observational study results of peripheral IVL featured as a late breaking presentation at the VIVA21 conference First one-year results, a new gender analysis and an OCT analysis from the Disrupt CAD coronary IVL clinical program presented in several sessions at the 32nd Transcatheter Cardiovascular..."
08/09/2021 8-K Quarterly results
06/29/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
03/25/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Shockwave Medical Reports Third Quarter 2020 Financial Results SANTA CLARA, Calif., Nov. 09, 2020 -- Shockwave Medical, Inc. , a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2020. Recent Highlights"
08/11/2020 8-K Quarterly results
07/20/2020 8-K Quarterly results
06/24/2020 8-K Submission of Matters to a Vote of Security Holders
06/19/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 SWAV Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rul...",
"Underwriting Agreement, by and among the Company and Morgan Stanley & Co. LLC and BofA Securities, Inc. as representatives of the several underwriters named therein",
"Opinion of Davis Polk & Wardwell LLP"
05/12/2020 8-K Quarterly results
Docs: "Investor Contact:"
04/06/2020 8-K Regulation FD Disclosure
02/13/2020 8-K Quarterly results
12/18/2019 8-K Quarterly results
11/07/2019 8-K Quarterly results
Docs: "SHOCKWAVE MEDICAL, INC. Balance Sheet Data September 30, 2019 December 31, 2018"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy